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• Mifepristone (RU486), which is used for early medical 
abortion, can only be obtained in Australia under the 
Authorised Prescriber legislation (Section 19[5] of the 
Therapeutic Goods Act 1989 [Cwlth]); two of the authors 
have permission to obtain, prescribe and administer this 
drug in Cairns, Queensland.
• From July 2006 to April 2007, 10 women who fulfilled the 
Therapeutic Goods Administration (TGA) criteria of “life-
threatening or otherwise serious” indications underwent 
medical abortion with mifepristone/misoprostol, and 
12 women conforming with abortion requirements of 
Queensland law, but not TGA legislation for mifepristone 
administration, had medical abortions with the less preferable 
methotrexate/misoprostol combination.
• Although it is now more than a year since the cross-party 
vote in federal Parliament in February 2006 confirmed wide 
support for the right of Australian women to a medical 
abortion, we believe we are at present the only medical 
practitioners in Australia with permission to use mifepristone.
• Obtaining Authorised Prescriber status from the TGA is of 
necessity a complex and protracted process, involving ethics 
committee approval and auditing, and regular reporting to 
the TGA.
• Because of the current restrictions, we believe that women 
seeking medical abortion in Australia face barriers not 
experienced by women in other comparable countries, and 
that drug manufacturing and distributing companies may be 
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discouraged from seeking to market mifepristone in Australia.ife
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The drugs are for a patient or patients, exclusively within the
practice of the applicant, whose clinical condition would benefit
from the drug. Before making the actual application, a practitioner
must obtain the approval of the ethics committee of either a
hospital in which he or she works or a professional college — this
approval is of the practitioner’s suitability to prescribe the particu-
lar drug, rather than of the evidence for use of the drug itself.
Having obtained ethics committee approval, the practitioner, in
making the application to the TGA, must include evidence for the
safety and effectiveness of the drug, as well as detailed protocols
for its use, copies of information to be supplied to patients, and
details of consent procedures. TGA approval is conditional upon
ongoing audit by the ethics committee of the use of the drug and
regular reporting to the TGA.1 The TGA legislation limits all drugs
administered by Authorised Prescribers to clinical indications that
are “life-threatening or otherwise serious”.
Approval of our suitability to administer the drug to appropriate
patients resident in Cairns was obtained from the Cairns Base
Hospital Ethics Committee. Cairns is a North Queensland city of
150 000 people, with an annual birth rate of 3000. Our applica-
tion to the TGA included an evidence-based list of medical
conditions that would be a threat to the life, or a major threat to
the health, of a pregnant woman continuing with the pregnancy.1
Our application was specifically for permission to use mifepristone
together with misoprostol for induced abortion at up to 9 weeks’
gestation, in accordance with the recommendations of the Royal
College of Obstetricians and Gynaecologists (RCOG).2
At the time our application was made, under the Therapeutic
Goods Amendment Act 1996 (Cwlth) (the “Harradine Amendment”),
mifepristone could only be imported into or used in Australia with
the personal permission of the federal Minister for Health. This
unique piece of legislation had the effect of making the drug
unavailable to Australian women from that date. However, in
February 2006, a Private Members’ Bill across party lines in the
federal Parliament overturned the Harradine Amendment, and the
decision about our application was thus made solely by the
TGA.3,4 In April 2006, we were granted permission to use the
drug, and in June 2006, we were issued with a permit to import 40
tablets from the non-profit New Zealand company Istar Ltd, which
in turn had imported the drug from the French manufacturers,
Exelgyn Laboratories.
These events generated considerable publicity, and in the past
12 months we have received more than 600 enquiries from women
and doctors throughout Australia relating to the use of mifepris-
tone for early abortion. These have been by telephone and email
— our email addresses and telephone numbers being in the public
domain — and have been in the approximate proportion of five
requests from women seeking abortion to each request from a
doctor either seeking information about the drug or wishing to
refer a patient. We have, however, been constrained in our practice
by the requirements of our TGA approval, and most of those
making the requests were referred to abortion counselling services
or providers of surgical abortion.
Use of mifepristone/misoprostol in Cairns, 
July 2006 – April 2007
In the first 10 months after receiving TGA permission, we
performed 10 early medical abortions using the mifepristone/ber 3 • 6 August 2007 171
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included: severe hypertension, severe pre-eclampsia/eclampsia in a
previous pregnancy, thromboembolic disease requiring long-term
anticoagulation, polycystic kidneys with recurrent urinary tract
infections, previous ruptured uterus in pregnancy, severe depres-
sion requiring antidepressant therapy, recent major breast and
pelvic floor surgery, and history of major fetal anomaly in a
previous pregnancy. Most women had more than one indication.
All women had the alternatives to abortion explained in a
consultation; in addition, the procedure was explained in detail,
and informed consent obtained. All women had an intrauterine
pregnancy of less than 63 days confirmed by ultrasound. The
regimen recommended by the RCOG of 200 mg mifepristone
orally, followed 48 hours later by 800 μg misoprostol intrava-
ginally, was used in all cases.2
Nine women underwent the abortion process at home in the
presence of a support person, while in close telephone contact
with us and readily able to access emergency care if required.
Analgesia and prophylactic antibiotics were prescribed. The abor-
tions took place at home within 4 hours of the insertion of
misoprostol, and there were no complications. The woman with a
history of uterine rupture at 33 weeks’ gestation in a previous
pregnancy (after perforation of the uterus during an earlier surgical
abortion) was admitted to hospital for the administration of
misoprostol, and the abortion proceeded without complication.
All women were seen at a follow-up appointment, which
included ultrasound scanning to confirm that the abortion was
complete, plus advice on contraception and prevention of sexually
transmitted infections.
Use of methotrexate/misoprostol in Cairns, 
July 2006 – April 2007
In the same time period, another 12 women requesting medical
termination of pregnancy were seen at the Sexual Health Clinic in
Cairns Base Hospital. The indications for abortion in these women,
although conforming with the requirements of Queensland law, in
our opinion fell short of those dictated by the TGA legislation for
mifepristone administration. These women underwent appropriate
consultations with two of us (D B R and H M McN) that were
exactly the same as those provided to the women in the mifepris-
tone group, and were administered methotrexate 50 mg orally. Five
to seven days later, 800 μg misoprostol was inserted intravaginally.
Again, the women underwent the abortion process at home with a
support person present. One woman required surgical completion
of an incomplete abortion; another woman bled vaginally for 7
days, but did not require transfusion or hospitalisation. Otherwise,
the procedures were uncomplicated. The same follow-up measures
were carried out as for the women given mifepristone/misoprostol.
Expanding access to mifepristone in Australia
In the period July 2006 – April 2007, there were approximately 2500
births in Cairns and 600 surgical abortions were performed. The
number of medical abortions carried out under the Authorised
Prescriber regulations therefore involved only a very small percentage
of the pregnant women cared for in Cairns in this time. Our motive
for reporting these cases is, firstly, to highlight the current clinical
situation in Australia, which is little different from that preceding the
overturning of the Harradine Amendment, and contrasts sharply
with that in the United States, the United Kingdom, most of Europe,
and elsewhere. Secondly, we wished to examine the barriers currently
in existence that prevent or inhibit other practitioners from offering
mifepristone to appropriate patients.
Medical abortion in early pregnancy using mifepristone/miso-
prostol, though widely available and largely non-controversial
overseas, is, at the time of writing, still available in Australia only
in Cairns and only within the very restricted framework of the
Authorised Prescriber legislation.5-7 Medical abortion using metho-
trexate/misoprostol has also been widely and safely used over-
seas.5-8 This method is known to be used in Australia, but to date
there have been no reports of this use in the medical literature.9 In
December 2006, Marie Stopes International announced the results
of a pilot program of methotrexate/misoprostol carried out at two
clinics in New South Wales — 36 women had undergone a
medical termination, with one woman subsequently requiring a
surgical termination for a continuing pregnancy, but there were no
other complications.10
The procedure for obtaining approval as an Authorised Pre-
scriber of a drug from the TGA is of necessity a complex and
protracted one. To date, through personal communication, we are
aware of four applications from other practitioners for the use of
mifepristone having been returned by the TGA with a request for
further information, and, at the time of writing, no application has
been approved for a pharmaceutical company to market the drug
nationally. (The TGA has reportedly declined to state publicly
whether any such applications have been received, as such
material is commercial-in-confidence.11)
We intend no criticism of the TGA in making these statements;
we appreciate the thoroughly professional approach of TGA
personnel in their evaluation of all drugs for use in Australia. In
fact, the Authorised Prescriber legislation is an inappropriate route
for large numbers of practitioners to access mifepristone; it can
nevertheless be said that, in approving mifepristone for our use,
the TGA has concluded from the evidence provided that the drug
is sufficiently safe and effective to be available for at least some
Australian women. However, the political debate surrounding the
drug would appear so far to have had the effect of discouraging
Australian drug manufacturing and distributing companies from
seeking to market mifepristone in Australia.
A further potential disincentive lies in the fact that mifepristone,
when used for induced abortion, is used in conjunction with
misoprostol. Misoprostol is licensed for use in Australia, as
elsewhere, only for the treatment of gastric ulceration, and there-
fore in all other situations is used “off-label” (ie, without specific
TGA approval).12 Such use of drugs off-label is a common and
accepted practice in Australian hospitals — misoprostol is widely
used for the treatment of postpartum haemorrhage and, less
commonly, for incomplete spontaneous miscarriage; and metho-
trexate, an anti-metabolite, is used for the treatment of unruptured
ectopic pregnancy.13,14 However, the need to inform all patients of
the off-label use of misoprostol, as our own protocols require, does
make the process of consultation for medical abortion more
prolonged, and could certainly complicate the application of a
pharmaceutical company to market mifepristone in Australia.
A call for proactive reform in access to abortion
Our recent experience of providing early medical abortion in
Cairns demonstrates vividly the conflicting situation facing women
currently seeking medical abortion in Australia. Whereas the
cross-party vote in the federal Parliament in February 2006, and172 MJA • Volume 187 Number 3 • 6 August 2007
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wide support for the right of Australian women to medical
abortion, a year later mifepristone use is restricted to a handful of
women in Cairns, and our colleagues appear to be experiencing
great difficulties obtaining approval to extend access to the drug.
Methotrexate/misoprostol is being offered to some Australian
women, although numbers are not known, and while this regimen
is both legal and safe, overseas experience shows mifepristone/
misoprostol to be more effective and to have a shorter time frame
for completion of the abortion process.15
Previous articles in the Journal have highlighted variations in
abortion law between Australian states, calling for reform and a
national approach to legislation and provision of abortion serv-
ices.16,17 At present, because of variations in the accessibility of
abortion among states and regions, many women are known to
have travelled hundreds of kilometres to obtain abortions, often
across state borders.18 If medical abortion were to become more
easily available in only certain parts of the country, our experience
suggests that such travel to obtain abortion would increase.
National availability of mifepristone would potentially redress
inequities of access to abortion services for Australian women,
especially rural women and those from certain ethnic groups.
There is an urgent need for a more proactive approach from
individual doctors, professional bodies and Health Departments,
at both state and federal level, to make mifepristone widely used
and largely uncontroversial, as it is in other countries, and
accessible to every Australian woman faced with making the
difficult decision about abortion for herself.
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